Kezar Life Sciences Inc (KZR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kezar Life Sciences Inc (KZR) has a cash flow conversion efficiency ratio of -0.114x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.45 Million) by net assets ($65.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kezar Life Sciences Inc market capitalisation for the company's overall valuation and market capitalisation.
Kezar Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Kezar Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kezar Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kezar Life Sciences Inc ranked by their cash flow conversion efficiency. See Kezar Life Sciences Inc (KZR) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inotiv Inc
NASDAQ:NOTV
|
-0.014x |
|
Onlineformapro SA
PA:MLONL
|
N/A |
|
Peel Hunt Ltd
LSE:PEEL
|
0.134x |
|
Barakah Offshore Petroleum Bhd
KLSE:7251
|
0.017x |
|
Silver Spruce Resources Inc
V:SSE
|
0.000x |
|
Consolidated Firstfund Capital Corp
V:FFP
|
-0.029x |
|
Biomx Inc
NYSE MKT:PHGE
|
-0.685x |
|
MFC Industrial Real Estate Investment Trust
BK:MIT
|
-25.926x |
Annual Cash Flow Conversion Efficiency for Kezar Life Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kezar Life Sciences Inc from 2016 to 2025. View today's stock price for Kezar Life Sciences Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.07 Million | $-51.78 Million | -0.739x | -16.41% |
| 2024-12-31 | $116.92 Million | $-74.21 Million | -0.635x | -45.83% |
| 2023-12-31 | $187.57 Million | $-81.64 Million | -0.435x | -99.62% |
| 2022-12-31 | $269.87 Million | $-58.85 Million | -0.218x | -1.16% |
| 2021-12-31 | $196.88 Million | $-42.44 Million | -0.216x | +17.76% |
| 2020-12-31 | $140.98 Million | $-36.95 Million | -0.262x | +31.54% |
| 2019-12-31 | $78.05 Million | $-29.88 Million | -0.383x | -100.31% |
| 2018-12-31 | $108.80 Million | $-20.79 Million | -0.191x | -160.54% |
| 2017-12-31 | $-25.69 Million | $-8.11 Million | 0.316x | -43.63% |
| 2016-12-31 | $-17.43 Million | $-9.76 Million | 0.560x | -- |
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more